Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status

AIDS Patient Care and STDs

Volumn 29, Issue 7, 2015, Pages 370-378

  Marcus, Julia L ^a   Leyden, Wendy A ^a   Chao, Chun R ^b   Xu, Lanfang ^b   Quesenberry, Charles P ^a   Tien, Phyllis C ^c,e   Klein, Daniel B ^b   Towner, William J ^b   Horberg, Michael A ^d   Silverberg, Michael J ^a  

^a DIVISION OF RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Mid Atlantic Permanente Research Institute   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; VIRUS RNA; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DEATH; FOLLOW UP; GENDER; HAZARD RATIO; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MORTALITY; NONHUMAN; TREATMENT OUTCOME; TREATMENT RESPONSE; AIDS RELATED COMPLEX; COHORT ANALYSIS; COMPLICATION; EPIDEMIOLOGY; FEMALE; HEPACIVIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INCIDENCE; KAPLAN MEIER METHOD; PROPORTIONAL HAZARDS MODEL; UNITED STATES; VIROLOGY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84934277005     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2015.0040     Document Type: Article

References (49)

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006;166:1632-1641
2. HIV/AIDS and Viral Hepatitis. 〈http://www.cdc.gov/hepatitis/Populations/HIV.htm〉 (Last accessedOctober 29, 2014).
3. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005;40:e101-e109.
4. Carmo RA, Guimaraes MD, Moura AS, et al. The influence of HCV co-infection on clinical, immunological and virological responses to HAART in HIV-patients. Braz J Infect Dis 2008;12:173-179.
5. Tsiara CG, Nikolopoulos GK, Dimou NL, et al. Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: A meta-analysis. J Viral Hepat 2013;20:715-724.
6. Weis N, Lindhardt BO, Kronborg G, et al. Impact of hepatitis C virus co-infection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: A nationwide cohort study. Clin Infect Dis 2006;42:1481-1487.
7. De Luca A, Bugarini R, Lepri AC, et al. Co-infection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002;162:2125-2132.
8. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: A meta-analysis. Clin Infect Dis 2005;41:713-720.
9. Shmagel KV, Saidakova EV, Korolevskaya LB, et al. Influence of hepatitis C virus co-infection on CD4+ T cells of HIV-infected patients receiving HAART. AIDS 2014;28:2381-2388.
10. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection. J Hepatol 2012;57:743-751.
11. van der Helm J, Geskus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013;144:751-760 e2.
12. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: Increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009;49:1605-1615.
13. Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, 2014.
14. Baden R, Rockstroh JK, Buti M. Natural history and management of hepatitis C: Does sex play a role? J Infect Dis 2014;209 Suppl 3:S81-S85.
15. Collazos J, Carton JA, Asensi V. Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients co-infected with human immunodeficiency virus. Curr HIV Res 2011;9:339-345.
16. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure. Hepatology 2004;40:1426-1433.
17. Thorsteinsson K, Ladelund S, Jensen-Fangel S, et al. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: A nationwide population-based cohort study. BMC Infect Dis 2012;12:293.
18. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: The gender issue revisited. J Acquir Immune Defic Syndr 2003;32:452-461.
19. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005;19:577-583.
20. Barber TJ, Geretti AM, Anderson J, et al. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011;16:805-814.
21. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007;21:835-843.
22. Zaragoza-Macias E, Cosco D, Nguyen ML, Del Rio C, Lennox J. Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population. AIDS Res Hum Retroviruses 2010;26:133-138.
23. Giordano TP, Wright JA, Hasan MQ, White AC, Jr, Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003;37:433-437.
24. Maskew M, Brennan AT, Westreich D, McNamara L, Mac- Phail AP, Fox MP. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt) 2013;22:113-120.
25. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmaco-kinetic profile: A review of sex differences. Gend Med 2007;4:106-119.
26. Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol 2011;51:1665-1673.
27. Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med 2010;11:299-307.
28. Carter A, Min JE, Chau W, et al. Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010). PLoS One 2014;9:e92334.
29. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2551-2559.
30. Gordon N. 2006. How Does the Adult Kaiser Permanente Membership in Northern California Compare with the Larger Community? 〈http://www.dor.kaiser.org/external/uploadedFiles/content/research/mhs/-2011-Revised-Site/Documents-Special-Reports/comparison-kaiser-vs-nonKaiser-adults-kpnc(1).pdf〉 (Last accessed February 18, 2015).
31. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 〈http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf〉 (Last accessed December 4, 2014).
32. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged < 18 months and for HIV infection and AIDS among children aged 18 months to < 13 years-United States, 2008. MMWR Recomm Rep 2008;57:1-12.
33. Elliott MN, Fremont A, Morrison PA, Pantoja P, Lurie N. A new method for estimating race/ethnicity and associated disparities where administrative records lack self-reported race/ethnicity. Health Serv Res 2008;43:1722-1736.
34. Fiscella K, Fremont AM. Use of geocoding and surname analysis to estimate race and ethnicity. Health Serv Res 2006;41:1482-1500.
35. Gameiro CM, Romao F, Castelo-Branco C. Menopause and aging: Changes in the immune system - A review. Maturitas 2010;67:316-320.
36. Fuping G, Wei L, Yang H, et al. Impact of hepatitis C virus co-infection on HAART in HIV-infected individuals: Multicentric observation cohort. J Acquir Immune Defic Syndr 2010;54:137-142.
37. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002;288:199-206.
38. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002.
39. Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A. CD8(+) T cell activation in women co-infected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008;197:1402-1407.
40. Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients co-infected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009;83:11407-11411.
41. Operskalski EA, Kovacs A. HIV/HCV co-infection: Pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011;8:12-22.
42. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses 2010;26:511-518.
43. Maini MK, Gilson RJ, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996;72:27-31.
44. McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007;45:S47-S56; discussion S66-S67.
45. Stenkvist J, Nystrom J, Falconer K, Sonnerborg A, Weiland O. Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. J Hepatol 2014;61:957-961.
46. Braitstein P, Justice A, Bangsberg DR, et al. Hepatitis C co-infection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006;20:323-331.
47. Gertsch A, Michel O, Locatelli I, et al. Adherence to antiretroviral treatment decreases during postpartum compared to pregnancy: A longitudinal electronic monitoring study. AIDS Patient Care STDS 2013;27:208-210.
48. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: Comparison with US Census Bureau data. Perm J 2012;16:37-41.
49. 2010. 2010 Quarterly HIV/AIDS Statistics. California Department of Public Health, Office of AIDS 〈http://www.cdph.ca.gov/data/statistics/Pages/OA2010QtrlyStats.aspx〉 (Last accessed November 18, 2014).